Moderna (MRNA) PT Raised to $35 at Needham & Company, Following Earnings
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Price: $247.37 +8.29%
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Rating Summary:
6 Buy, 21 Hold, 4 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 15 | Down: 24 | New: 12
Join SI Premium – FREE
Needham & Company analyst Alan Carr raised the price target on Moderna (NASDAQ: MRNA) to $35.00 (from $28.00) while maintaining a Hold rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Moderna (MRNA) call put ratio 1.1 calls to 1 put into quarter results
- Duolingo Inc. (DUOL) PT Raised to $180 at DA Davidson
- Marriott International (MAR) PT Raised to $445 at Bernstein SocGen Group
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Needham & Company, Earnings, Alan CarrSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
